493 related articles for article (PubMed ID: 27856754)
1. Mouse model for acute Epstein-Barr virus infection.
Wirtz T; Weber T; Kracker S; Sommermann T; Rajewsky K; Yasuda T
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13821-13826. PubMed ID: 27856754
[TBL] [Abstract][Full Text] [Related]
2. Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.
Minamitani T; Ma Y; Zhou H; Kida H; Tsai CY; Obana M; Okuzaki D; Fujio Y; Kumanogoh A; Zhao B; Kikutani H; Kieff E; Gewurz BE; Yasui T
Proc Natl Acad Sci U S A; 2017 May; 114(18):4751-4756. PubMed ID: 28351978
[TBL] [Abstract][Full Text] [Related]
3. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
Ma SD; Tsai MH; Romero-Masters JC; Ranheim EA; Huebner SM; Bristol JA; Delecluse HJ; Kenney SC
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077657
[TBL] [Abstract][Full Text] [Related]
4. Germinal center cytokine driven epigenetic control of Epstein-Barr virus latency gene expression.
Liao Y; Yan J; Beri NR; Giulino-Roth L; Cesarman E; Gewurz BE
PLoS Pathog; 2024 Apr; 20(4):e1011939. PubMed ID: 38683861
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.
Vrazo AC; Chauchard M; Raab-Traub N; Longnecker R
PLoS Pathog; 2012; 8(4):e1002662. PubMed ID: 22536156
[TBL] [Abstract][Full Text] [Related]
6. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
7. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
8. [Molecular biological properties of the Epstein-Barr virus LMP1 gene: structure, function and polymorphism].
Smirnova KV; Diduk SV; Senyuta NB; Gurtsevitch VE
Vopr Virusol; 2015; 60(3):5-13. PubMed ID: 26281300
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
[TBL] [Abstract][Full Text] [Related]
10. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
11. Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus.
Martin HJ; Lee JM; Walls D; Hayward SD
J Virol; 2007 Sep; 81(18):9748-58. PubMed ID: 17609264
[TBL] [Abstract][Full Text] [Related]
12. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
14. Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1.
Zhou H; Guo W; Long C; Wang H; Wang J; Sun X
Biochem Biophys Res Commun; 2015 Jan; 456(3):815-20. PubMed ID: 25511707
[TBL] [Abstract][Full Text] [Related]
15. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
[TBL] [Abstract][Full Text] [Related]
16. Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells: implications for the pathogenesis of hemophagocytic syndrome.
Lay JD; Chuang SE; Rowe M; Su IJ
J Biomed Sci; 2003; 10(1):146-55. PubMed ID: 12607539
[TBL] [Abstract][Full Text] [Related]
17. EBV-NK cells interactions and lymphoproliferative disorders.
Kanegane H; Yachie A; Miyawaki T; Tosato G
Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
[TBL] [Abstract][Full Text] [Related]
18. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses.
Uchida J; Yasui T; Takaoka-Shichijo Y; Muraoka M; Kulwichit W; Raab-Traub N; Kikutani H
Science; 1999 Oct; 286(5438):300-3. PubMed ID: 10514374
[TBL] [Abstract][Full Text] [Related]
19. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
Islas-Ohlmayer M; Padgett-Thomas A; Domiati-Saad R; Melkus MW; Cravens PD; Martin Mdel P; Netto G; Garcia JV
J Virol; 2004 Dec; 78(24):13891-900. PubMed ID: 15564497
[TBL] [Abstract][Full Text] [Related]
20. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils.
Hudnall SD; Ge Y; Wei L; Yang NP; Wang HQ; Chen T
Mod Pathol; 2005 Apr; 18(4):519-27. PubMed ID: 15696119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
